Therapeutic Response Statement (Sensitivity)

This therapeutic response statement supports the relationship that PD-L1 (TAP) >= 1% status confers therapeutic sensitivity to Oxaliplatin, Paclitaxel, Tislelizumab in patients with Esophageal Squamous Cell Carcinoma.

This statement is based on a regulatory approval from the Food and Drug Administration:

TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (>=1).

Citation

BeOne Medicines USA, Inc. Tevimbra (tislelizumab-jsgr) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761232s013lbl.pdf. Revised December 2025. Accessed December 26, 2025.